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Streptozotocin–nicotinamideAbstract The present work describes the synthesis of 6-substituted-3-(1-(4-substituted)-4-((Z)-(5,
6-dimethoxy-1-oxo-1H-inden-2(3H)-ylidene)methyl)-1H-pyrazol-3-yl)-2H-chromen-2-one derivatives
(5a–l) by Claisen–Schmidt condensation of 3-(6-substituted-2-oxo-2H-chromen-3-yl)-1-(4-substi-
tuted)-1H-pyrazole-4-carbaldehyde derivatives (4a–l) with 5,6-dimethoxy-2,3-dihydro-1H-inden-1-
one at reﬂux temperature for 8 h. The synthesized compounds were screened for in vitro antioxidant
activity. Compounds 5e and 5g showed promising DPPH radical scavenging activity with IC50
54.14–56.19 lg/mL, ferrous ion chelating ability with IC50 53.75–56.89 lg/mL and reductive capabil-
ity with IC50 58.01–62.57 lg/mL. The selected compounds were also tested for in vivo antihypergly-
cemic activity against Streptozotocin–nicotinamide induced Adult Wistar rats. Compounds 5e and
5g showed signiﬁcant decrease in glucose concentration (115 and 138 mg/dL) with the dose of
100 mg/kg.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Human bodies are protected from oxidative stress by natural
enzymatic and non-enzymatic antioxidant defensive system,
whose capacity is affected by age, diet, and health status of
the individual (Chun et al., 2003). Therefore, only endogenous
antioxidant defenses are not absolutely efﬁcient. Dietary
antioxidants are required to diminish the cumulative effects
of oxidative damage due to excess ROS (reactive oxygen
species) that remains in our system (Lim and Murtijaya,nt anti-
2 R. Kenchappa et al.2007).These free radicals may oxidize nucleic acids, proteins,
or lipids which occur through a chain reaction and may form
potentially toxic end products (Guo et al., 2005; Chunhuan
et al., 2010). Therefore, oxidation can cause not only deterio-
ration of foodstuffs but also harm living organisms.
When free radicals overcome our body’s ability to neutral-
ize them, they attack the body itself. As a result free radicals
disturb the action of cellular DNA, which directs key cellular
activities. Cells with damaged DNA stagnate and are prone
to developing cancer and growths. This kind of damage also
accelerates the aging process and diabetes (Hyun et al., 2006)
directly causing wrinkles and age spots and severely taxing
the immune system. They may also responsible for other dis-
eases such as cardiovascular diseases (Singh and Jialal,
2006), neural disorders (Sas et al., 2007), Alzheimer’s disease
(Smith et al., 2000), alcohol-induced liver disease (Arteel
et al., 2006). Therefore, the searches for new antioxidants have
received much attention.
Diabetes mellitus is a chronic and multifactorial disease
characterized by a high level of blood glucose and impaired
insulin action (Neogi et al., 2003; Saltiel et al., 2001). It gener-
ally results in decrease in insulin secretion that translates into
impaired carbohydrate (glucose) use, which is the characteris-
tic feature of diabetes mellitus. This, results in hyperglycemia
in the blood, which could potentially cause serious debilitating
conditions including cardiovascular morbidity, nerve damage,
and mortality (Gegory et al., 2001). Non-insulin dependent
diabetes mellitus (NIDDM) accounts for approximately 80–
90% of all diabetes cases (King and Rewers, 1993). Although
signiﬁcant progress has been achieved in the treatment of type-
2 diabetes mellitus (T2DM) over last decade, the biochemical
and molecular mechanisms underlying insulin resistance have
not been clearly indicated (Kus et al., 2011; Sangle et al.,
2012). Therefore, it is essential to control blood glucose levels
during the early stages of the disease.
Coumarins, a group of benzopyrone derivatives (Saija
et al., 1995), have been recognized as one of the largest and
most widespread class of plant constituents occurring through-
out the plant kingdom (Es-Saﬁ et al., 2007; Anju et al., 2012).
Moreover coumarin containing other heterocyclic compounds
have been found to exhibit various pharmacological activities
including spasmolytic, antioxidant, anticoagulant, antiviral
(Stancho et al., 2008; Jovanovic et al., 1994), antimicrobial
(Chimenti et al., 2010; Vijaya Laxmi et al., 2013), analgesic
(Khan et al., 2005; Ghate et al., 2005), antitubercular (Karali
et al., 2002), antimalarial (Gajanan et al., 2010), antidiabetic
(Gireesh et al.,2011) and antitumor (Xin-Hua et al., 2012)
activities.
Pyrazoline derivatives have exhibited various biological
activities such as antioxidant, antimicrobial (Ahmad et al.,
2010; Padmaja et al., 2011; Mamta et al., 2010), analgesic,
anti-inﬂammatory (Isloor et al., 2000), anti-hyperglycemic
and sedative-hypnotic activities (Braulio et al., 1999; Rizk
et al., 2011).
Prompted by the above results and in continuation of our
research work on biologically active compounds (Kenchappa
et al., 2013a,b) we synthesized coumarin derivatives containing
pyrazole and indenone moiety and screened them for antioxi-
dant and antidiabetic activities.Please cite this article in press as: Kenchappa, R. et al., Synthesis of couma
oxidant and antihyperglycemic agents. Arabian Journal of Chemistry (2012. Materials and methods
2.1. Chemistry
5,6-Dimethoxyindenone with 98% purity was purchased from
Sigma Aldrich Company. Melting points were recorded on an
electro thermal melting point apparatus and are uncorrected.
1H and 13CNMR spectra were recorded on a Bruker
400 MHz spectrometer and chemical shifts are shown in d val-
ues (ppm) with tetramethylsilane (TMS) as internal standard.
LC–MS was obtained using an Agilent LC/MS instrument
(Electronic Ionization method). The FT-IR spectra were taken
in KBr pellets (100 mg) using a Shimadzu FT-IR spectropho-
tometer. Column chromatography was performed using silica
gel (230–400 mesh), silica gel GF254 plates from Merck were
used for TLC and spots were identiﬁed either by UV or dip-
ping the plates in potassium permanganate solution.
2.1.1. General procedure for the synthesis of 3-(6-substituted-2-
oxo-2H-chromen-3-yl)-1-(4-substituted)-1H-pyrazole-4-
carbaldehyde derivatives (4a-l)
To the cold solution of DMF (1.0 mL, 0.014 mol), POCl3
(1.3 mL 0.014 mol) was added drop wise for half an hour by
maintaining the temperature at 0–5 C. To this solution, 3-
[(1E)-1-(2-phenylhydrazinylidene) ethyl]-2H-chromen-2-one
(0.0035 mol) (3a–l) was added and the reaction mixture was
stirred. After complete addition, the stirring was continued
for 30 min, at 0–5 C and then the temperature was raised to
80 C for about 6 h. Completion of reaction was conﬁrmed
by TLC, reaction mixture was poured into crushed ice and
neutralized by 10% NaOH solution. The solid precipitated
out was ﬁltered, dried and recrystallized from ethanol.
The formation of compounds 4a (m.p.; 183–186 C) and 4b
(m.p.;185 to 187 C) was conﬁrmed by comparing its melting
points with the literature value (Vijaya Laxmi et al., 2013).
2.1.2. 1-(4-Chlorophenyl)-3-(2-oxo-2H-chromen-3-yl)-1H-
pyrazole-4-carbaldehyde (4c)
Yield 70%; m.p. 189–192 C; Mol. Formula: C19H11ClN2O3;
IR (KBr, cm1): 1714 (C‚O), 1675 (CHO), 1625 (C‚N),
1590 (C‚C); 1H NMR (DMSO-d6, 400 MHz) d: 7.30–8.10
(m, 9H), 9.43 (s, 1H), 10.22 (s, 1H).MS: m/z= 370 [M+],
372 [M+2].
2.1.3. 3-(6-Bromo-2-oxo-2H-chromen-3-yl)-1-(4-
chlorophenyl)-1H-pyrazole-4-carbaldehyde (4d)
Yield 75%; m.p. 189–192 C; Mol. Formula: C19H10BrClN2-
O3; IR (KBr, cm
1): 1700 (C‚O), 1671 (CHO), 1621
(C‚N), 1592 (C‚C); 1H NMR (DMSO-d6, 400 MHz)
d:7.31–8.15 (m, 8H), 9.45 (s, 1H), 10.23 (s, 1H).MS: m/
z= 430 [M+], 432 [M+2], 434 [M+4].
2.1.4. 1-(4-Methylphenyl)-3-(2-oxo-2H-chromen-3-yl)-1H-
pyrazole-4-carbaldehyde (4e)
Yield 72%; m.p. 194–197 C; Mol. Formula: C20H14N2O3; IR
(KBr, cm1): 1710 (C‚O), 1689 (CHO), 1625 (C‚N), 1588
(C‚C); 1HNMR (DMSO-d6, 400 MHz) d: 3.20 (s, 3H,
CH3), 7.20–7.93 (m, 9H), 9.40 (s, 1H), 9.97 (s, 1H).MS: m/
z= 330 [M+].rin derivatives containing pyrazole and indenone rings as potent anti-
4), http://dx.doi.org/10.1016/j.arabjc.2014.05.029
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-1-(4-methylphenyl)-1H-pyrazole-4-carbaldehyde (4f)
Yield 68%; m.p.199–202 C; Mol. Formula: C20H13BrN2O3;
IR (KBr, cm1): 1715 (C‚O), 1691 (CHO), 1621 (C‚N),
1585 (C‚C); 1HNMR (DMSO-d6, 400 MHz) d: 3.25(s, 3H,
CH3), 7.22–8.10 (m, 8H), 9.43 (s, 1H), 10.10 (s, 1H). MS: m/
z= 408 [M+], 410 [M+2].
2.1.6. 1-(4-Methoxyphenyl)-3-(2-oxo-2H-chromen-3-yl)
-1H-pyrazole-4-carbaldehyde (4g)
Yield 77%; m.p. 177–180 C; Mol. Formula: C20H14N2O4; IR
(KBr, cm1): 1718 (C‚O), 1685(CHO), 1618 (C‚N), 1595
(C‚C); 1HNMR (DMSO-d6, 400 MHz) d: 3.88 (s, 3H,
OCH3), 7.13–8.06 (m, 9H), 9.42 (s, 1H), 9.94 (s, 1H).MS: m/
z= 346.33 [M+].
2.1.7. 3-(6-Bromo-2-oxo-2H-chromen-3-yl)-1
-(4-methoxyphenyl)-1H-pyrazole-4-carbaldehyde (4h)
Yield 78%; m.p. 181–183 C; Mol. Formula: C20H13BrN2O4;
IR (KBr, cm1): 1712 (C‚O), 1687 (CHO), 1620
(C‚N),1591 (C‚C); 1H NMR (DMSO-d6, 400 MHz) d:
3.35(s, 3H, OCH3), 7.30–8.13 (m, 8H), 9.43 (s, 1H), 10.21 (s,
1H). MS: m/z= 424 [M+], 426 [M+2].
2.1.8. 1-(4-Nitrophenyl)-3-(2-oxo-2H-chromen-3-yl)
-1H-pyrazole-4-carbaldehyde (4i)
Yield 75%; m.p. 189–192 C; Mol. Formula: C19H11N3O5; IR
(KBr, cm1): 1721 (C‚O), 1681 (CHO), 1620 (C‚N), 1599
(C‚C); 1H NMR (DMSO-d6, 400 MHz) d: 6.90–8.0 (m,
9H), 9.43 (s, 1H), 10.01 (s, 1H).MS: m/z= 361 [M+].
2.1.9. 3-(6-Bromo-2-oxo-2H-chromen-3-yl)-1-(4-nitrophenyl)
-1H-pyrazole-4-Carbaldehyde (4j)
Yield 76%; m.p.187–189 C; Mol. Formula: C19H10BrN3O5;
IR (KBr, cm1): 1719 (C‚O), 1684 (CHO), 1630 (C‚N),
1625, 1520 (NAO), 1585 (C‚C); 1HNMR (DMSO-d6,
400 MHz) d: 6.95–8.05 (m, 8H), 9.48 (s, 1H), 10.15 (s,
1H).MS: m/z= 439 [M+], 441 [M+2].
2.1.10. 1-(4-Fluorophenyl)-3-(2-oxo-2H-chromen-3-yl)-1H
-pyrazole-4-carbaldehyde (4k)
Yield 72%; m.p. 161–164 C; Mol. Formula: C19H11FN2O3;
IR (KBr, cm1): 1709 (C‚O), 1680 (CHO), 1611 (C‚N),
1603 (C‚C); 1H NMR (DMSO-d6, 400 MHz) d: 7.13–8.06
(m, 9H), 9.45 (s, 1H), 9.98 (s, 1H).MS: m/z= 334 [M+].
2.1.11. 3-(6-Bromo-2-oxo-2H-chromen-3-yl)-1
-(4-ﬂuorophenyl)-1H-pyrazole-4-carbaldehyde (4l)
Yield 68%; m.p. 166–168 C; Mol. Formula: C19H10BrFN2O3; IR
(KBr, cm1): 1705 (C‚O), 1682 (CHO), 1618 (C‚N), 1589
(C‚C); 1HNMR (DMSO-d6, 400 MHz) d: 7.10–8.0 (m, 8H),
9.42 (s, 1H), 10.12 (s, 1H).MS: m/z=412 [M+], 414 [M+2].
2.1.12. Synthesis of 3-(4-((Z)-(5,6-dimethoxy-1-oxo-1H-
inden-2(3H)-ylidene) methyl)-1-4-substituted-phenyl-1H-
pyrazol-3-yl)-6-substituted-2H-chromen-2-onederivatives
(5a–l)
The mixture of 5,6-dimethoxy-2,3-dihydro-1H-inden-1-one
(0.5 g 0.002 mol) and 3-(6-substituted-2-oxo-2H-chromen-3-yl)-Please cite this article in press as: Kenchappa, R. et al., Synthesis of couma
oxidant and antihyperglycemic agents. Arabian Journal of Chemistry (2011-(4-substituted)-1H-pyrazole-4-carbaldehyde (4a–l) (0.002 mol)
was stirred in sodium methoxide solution under reﬂux condi-
tion for 8 h. and completion of the reaction was conﬁrmed
by TLC. The reaction mixture was poured into cold water
and neutralized with dilute HCl. The solid separated was
ﬁltered, dried and recrystallized with ethanol to furnish the
title compounds.
2.1.13. 3-(4-((Z)-(5,6-Dimethoxy-1-oxo-1H-inden-2(3H)-
ylidene) methyl)-1-phenyl-1H-pyrazol-3-yl)-2H-chromen-2-one
(5a)
Yield 73%; m.p. 224–227 C; Mol. Formula: C30H22N2O5; IR
(KBr, cm1): 3063 (ArAH), 1705 (coumarin C‚O), 1678
(indenone C‚O), 1619 (C‚N), 1596 (C‚C); 1HNMR
(DMSO-d6, 400 MHz) d: 3.28 (3H, s, OCH3), 3.41 (3H, s,
OCH3), 4.75 (2H, s, CH2), 7.39–8.89 (12 H, m, ArAH), 8.90
(1H, s, CH-methine), 9.80 (1H, s, C‚CAH), 13CNMR
(CDCl3) d: 48.9 (CH2), 57.8 (2-OCH3), 102.2, 103.1, 108.0,
110.5 (2C), 112.1, 114.3, 118.4, 119.5, 122.3, 123.2, 126.5,
129.1, 130.1 (2C), 131.2, 132.8, 138.5, 139.8, 142.9, 148.4,
150.1, 152.4, 159.6, 161.5, 168.2 (coumarin C‚O), 171.5 (inde-
none C‚O).MS: m/z 490.50 [M+].
2.1.14. 6-Bromo-3-(4-((Z)-(5,6-dimethoxy-1-oxo-1H
-inden-2(3H)-ylidene) methyl)-1-phenyl-1H-pyrazol-3-yl)
-2H-chromen-2-one (5b)
Yield 71%; m.p. 221–223 C; Mol. Formula: C30H21BrN2O5;
IR (KBr, cm1): 3060 (ArAH), 1707 (coumarin C‚O), 1670
(indenone C‚O), 1610 (C‚N), 1590 (C‚C); 684 (CABr);
1H NMR (DMSO-d6, 400 MHz) d: 3.00 (3H, s, OCH3), 3.09
(3H, s,OCH3), 4.33 (2H, s, CH2), 7.09–8.53 (11 H, m, ArAH),
8.56 (1H, s, CH methine), 9.68 (1H, s, C‚CAH),13CNMR
(CDCl3) d: 49.0 (CH2), 57.9 (2-OCH3), 103.2, 104.1, 109.0,
111.6 (2C), 113.2, 116.3, 119.3, 121.5, 123.5, 125.5, 128.6,
131.1, 132.1 (2C), 133.1, 135.8, 139.5, 141.8, 143.6, 150.4,
153.1, 155.4, 161.6, 165.5, 169.2 (coumarin C‚O), 175.5 (inde-
none C‚O).MS: m/z 568 [M+], 570 [M+2].
2.1.15. 3-(1-(4-Chlorophenyl)-4-((Z)-(5,6-dimethoxy-1
-oxo-1H-inden-2(3H)-ylidene)methyl)-1H-pyrazol-3-yl)
-2H-chromen-2-one (5c)
Yield 81%; m.p. 233–225 C; Mol. Formula: C30H21ClN2O5;
IR (KBr, cm1): 3052 (ArAH), 1703 (coumarin C‚O), 1675
(indenone C‚O), 1615 (C‚N), 1604 (C‚C); 680 (CACl);
1H NMR (DMSO-d6, 400 MHz) d: 3.20 (3H, s, OCH3), 3.39
(3H, s,OCH3), 4.65 (2H, s, CH2), 7.31–8.82 (11 H, m, ArAH),
8.82 (1H, s, CH methine), 9.69 (1H, s, C‚CAH),13CNMR
(CDCl3) d: 45.0 (CH2), 57.9 (2-OCH3), 103.6, 104.7, 109.7,
112.0 (2C), 113.7, 117.1, 119.5, 122.0, 123.7, 126.0, 128.9,
131.5, 133.1 (2C), 134.1, 136.2, 139.5, 142.0, 144.2, 151.4,
153.1, 156.4, 161.6, 166.5, 169.2 (coumarin C‚O), 176.5 (inde-
none C‚O).MS: m/z 524[M+], 526 [M+2].
2.1.16. 6-Bromo-3-(1-(4-chlorophenyl)-4-((Z)-(5,6-
dimethoxy-1-oxo-1H-inden-2(3H)-ylidene) methyl)
-1H-pyrazol-3-yl)-2H-chromen-2-one (5d)
Yield 82%; m.p. 241–243 C; Mol. Formula: C30H20BrClN2-
O5; IR (KBr, cm
1): 3060 (ArAH), 1713 (coumarin C‚O),
1678 (indenone C‚O), 1610 (C‚N), 1605 (C‚C); 687
(CABr), 680 (CACl); 1H NMR (DMSO-d6, 400 MHz) d:rin derivatives containing pyrazole and indenone rings as potent anti-
4), http://dx.doi.org/10.1016/j.arabjc.2014.05.029
4 R. Kenchappa et al.3.24 (3H, s, OCH3), 3.37 (3H, s,OCH3), 4.71 (2H, s, CH2),
7.35–8.85 (10H, m, ArAH), 8.86 (1H, s, CH methine), 9.74
(1H, s, C‚CAH), 13CNMR (CDCl3) d: 45.0 (CH2), 57.9 (2-
OCH3), 102.6, 104.7, 109.7, 112.0 (2C), 114.7, 116.1, 120.5,
122.0, 123.7, 125.0, 127.9, 130.0, 132.5 (2C), 134.1, 136.7,
139.5, 142.0, 144.2, 150.4, 153.1, 156.4, 162.2, 165.1, 169.0
(coumarin C‚O), 175.5 (indenone C‚O).MS: m/z 602[M+],
604 [M+2], 606 [M+4].
2.1.17. 3-(4-((Z)-(5,6-Dimethoxy-1-oxo-1H-inden-2(3H)-
ylidene) methyl)-1-p-tolyl-1H-pyrazol-3-yl)-2H-chromen-2-one
(5e)
Yield 72%; m.p. 242–245 C; Mol. Formula: C31H24N2O5; IR
(KBr, cm1): 3060 (ArAH), 1703 (coumarin C‚O), 1667 (inde-
none C‚O), 1615 (C‚N), 1605 (C‚C); 1H NMR (DMSO-d6,
400 MHz) d:2.52 (3H, s, CH3)3.22 (3H, s, OCH3), 3.35 (3H,
s,OCH3), 4.72 (2H, s, CH2), 7.36–8.86 (11H, m, ArAH), 8.88
(1H, s, CHmethine), 9.73 (1H, s, C‚CAH), 13CNMR (CDCl3)
d: 25.6 (CH3), 43.0 (CH2), 57.1 (2-OCH3), 103.2, 105.2, 108.6,
112.0 (2C), 114.7, 116.1, 119.5, 122.0, 123.5, 125.0, 127.9,
130.0, 132.2 (2C), 134.1, 136.5, 138.2, 142.3, 144.7, 151.1,
154.1, 157.1, 161.4, 165.1, 168.0 (coumarin C‚O), 174.2 (inde-
none C‚O). MS: m/z 504 [M+].
2.1.18. 6-Bromo-3-(4-((Z)-(5,6-dimethoxy-1-oxo-1H-inden-
2(3H)-ylidene) methyl)-1-p-tolyl-1H-pyrazol-3-yl)-2H-
chromen-2-one (5f)
Yield 68%; m.p. 251–253 C; Mol. Formula: C31H23BrN2O5;
IR (KBr, cm1): 3068 (ArAH), 1710 (coumarin C‚O), 1669
(indenone C‚O), 1617 (C‚N), 1600 (C‚C); 687 (CABr);
1H NMR (DMSO-d6, 400 MHz) d: 2.50 (3H, s, CH3)3.25
(3H, s, OCH3), 3.38 (3H, s,OCH3), 4.72 (2H, s, CH2), 7.35–
8.85 (10H, m, ArAH), 8.87 (1H, s, CH methine), 9.77 (1H, s,
C‚CAH),13CNMR (CDCl3) d: 24.3 (CH3), 44.0 (CH2), 57.6
(2-OCH3), 102.2, 105.2, 107.6, 112.0 (2C), 113.7, 116.1,
119.5, 121.0, 123.5, 125.0, 127.0, 130.0, 132.2 (2C), 134.1,
136.5, 138.2, 142.3, 144.7, 152.1, 154.1, 157.1, 162.4, 165.1,
168.9 (coumarin C‚O), 175.3 (indenone C‚O). MS: m/z
582 [M+], 584 [M+2].
2.1.19. 3-(4-((Z)-(5,6-Dimethoxy-1-oxo-1H-inden-2(3H)-
ylidene) methyl)-1-(4-methoxy phenyl)-1H-pyrazol-3-yl)-2H-
chromen-2-one (5g)
Yield 74%; m.p. 228–231 C; Mol. Formula: C31H24N2O6; IR
(KBr, cm1): 2989 (ArAH), 1712 (coumarin C‚O), 1687 (inde-
none C‚O), 1624 (C‚N), 1603 (C‚C); 1H NMR (DMSO-d6,
400 MHz) d: 2.78 (3H, s, OCH3)3.30 (3H, s, OCH3), 3.40 (3H,
s,OCH3), 4.34 (2H, s, CH2), 7.40–8.90(11H, m, ArAH), 8.90
(1H, s, CHmethine), 9.82 (1H, s, C‚CAH), 13CNMR (CDCl3)
d: 25.3 (OCH3), 45.0 (CH2), 58.6 (2-OCH3), 103.2, 105.2, 107.8,
112.0 (2C), 114.7, 116.1, 119.0, 121.0, 122.9, 125.0, 127.0, 129.5,
132.2 (2C), 134.1, 136.3, 139.2, 142.3, 146.7, 152.1, 155.1, 157.1,
161.4, 166.1, 168.9 (coumarin C‚O), 174.3 (indenone
C‚O).MS: m/z 520 [M+].
2.1.20. 6-Bromo-3-(4-((Z)-(5,6-dimethoxy-1-oxo-1H-inden-
2(3H)-ylidene)methyl)-1-(4-methoxy phenyl)-1H-pyrazol-3-
yl)-2H-chromen-2-one (5h)
Yield 76%; m.p. 234–237 C; Mol. Formula: C31H23BrN2O6;
IR (KBr, cm1): 2995 (ArAH), 1709 (coumarin C‚O), 1681Please cite this article in press as: Kenchappa, R. et al., Synthesis of couma
oxidant and antihyperglycemic agents. Arabian Journal of Chemistry (201(indenone C‚O), 1621 (C‚N), 1600 (C‚C), 687 (CABr); 1H
NMR (DMSO-d6, 400 MHz) d: 2.76 (3H, s, CH3) 3.29 (3H, s,
OCH3), 3.42 (3H, s,OCH3), 4.76 (2H, s, CH2), 7.42–8.91 (10H,
m, ArAH), 8.92 (1H, s, CH methine), 9.84 (1H, s, C‚CAH),
13CNMR(CDCl3) d: 25.5 (OCH3), 46.0 (CH2), 57.2 (2-OCH3),
102.3, 105.2, 106.8, 111.0 (2C), 114.7, 116.1, 118.0, 121.0,
123.5, 125.0, 127.0, 129.3, 132.0 (2C), 134.2, 136.9, 139.2,
142.5, 145.6, 151.1, 155.2, 158.4, 161.4, 165.4, 169.0 (coumarin
C‚O), 175.3 (indenone C‚O).MS:m/z 598 [M+], 600 [M+2].
2.1.21. 3-(4-((Z)-(5,6-Dimethoxy-1-oxo-1H-inden-2(3H)-
ylidene) methyl)-1-(4-nitro phenyl)-1H-pyrazol-3-yl)-2H-
chromen-2-one (5i)
Yield 81%; m.p. 267–270 C; Mol. Formula: C30H21N3O7; IR
(KBr, cm1): 2995 (ArAH), 1709 (coumarin C‚O), 1676
(indenone C‚O), 1626 (C‚N), 1598 (C‚C), 1553 (NO2);
1H NMR (DMSO-d6, 400 MHz) d: 3.28 (3H, s, OCH3), 3.40
(3H, s,OCH3), 4.75 (2H, s, CH2), 7.44–8.92 (11H, m, ArAH),
8.93 (1H, s, CH methine), 9.83 (1H, s, C‚CAH), 13CNMR
(CDCl3) d: 46.0 (CH2), 58.1 (2-OCH3), 103.4, 105.2, 107.8,
111.0 (2C), 113.7, 116.1, 118.0, 121.3, 123.5, 125.3, 127.0,
129.3, 131.4 (2C), 134.2, 137.4, 139.2, 142.5, 145.3, 152.3,
155.2, 157.3, 160.4, 164.4, 168.0 (coumarin C‚O), 176.3 (inde-
none C‚O). MS: m/z 535 [M+].
2.1.22. 6-Bromo-3-(4-((Z)-(5,6-dimethoxy-1-oxo-1H-inden-
2(3H)-ylidene) methyl)-1-(4-nitro phenyl)-1H-pyrazol-3-yl)-
2H-chromen-2-one(5j)
Yield 82%; m.p. 278–28 C; Mol. Formula: C30H20BrN3O7;
IR (KBr, cm1): 3016 (ArAH), 1703 (coumarin C‚O), 1686
(indenone C‚O), 1620 (C‚N), 1596 (C‚C), 1552 (NO2);
1H NMR (DMSO-d6, 400 MHz) d:2.97 (3H, s, OCH3), 3.06
(3H, s,OCH3), 4.30 (2H, s, CH2), 7.06–8.49(10H, m, ArAH),
8.50 (1H, s, CH methine), 9.72 (1H, s, C‚CAH),13CNMR
(CDCl3) d: 45.0 (CH2), 57.1 (2-OCH3), 102.4, 105.2, 108.2,
111.0 (2C), 113.7, 115.5, 118.0, 121.4, 123.5, 125.3, 128.0,
131.5, 133.4 (2C), 136.2, 138.4, 141.2, 144.5, 148.3, 152.3,
155.2, 158.3, 162.4, 165.4, 169.0 (coumarin C‚O), 175.3 (inde-
none C‚O).MS: m/z 613[M+], 615 [M+2].
2.1.23. 3-(1-(4-Fluorophenyl)-4-((Z)-(5,6-dimethoxy-1-oxo-
1H-inden-2(3H)-ylidene)methyl)-1H-pyrazol-3-yl)-2H-
chromen-2-one (5k)
Yield 77%; m.p. >300 C; Mol. Formula: C30H21FN2O5; IR
(KBr, cm1): 3016 (ArAH), 1705 (coumarin C‚O), 1684
(indenone C‚O), 1620 (C‚N), 1596 (C‚C), 1552 (NO2);
1H NMR (DMSO-d6, 400 MHz) d: 3.26 (3H, s, OCH3), 3.42
(3H, s,OCH3), 4.70 (2H, s, CH2), 7.33–8.83 (11 H, m, ArAH),
8.85 (1H, s, CH methine), 9.75 (1H, s, C‚CAH),13CNMR
(CDCl3) d: 43.0 (CH2), 56.2 (2-OCH3), 103.4, 106.2, 109.3,
111.0 (2C), 114.7, 116.5, 118.0, 120.4, 122.5, 125.3, 127.0,
130.5, 133.4 (2C), 136.2, 138.4, 143.4, 145.2, 148.3, 153.3,
155.2, 159.3, 162.4, 166.4, 169.0 (coumarin C‚O), 176.3 (inde-
none C‚O). MS: m/z 508 [M+].
2.1.24. 6-Bromo-3-(1-(4-ﬂuorophenyl)-4-((Z)-(5,6-
dimethoxy-1-oxo-1H-inden-2(3H)-ylidene) methyl)-1H-
pyrazol-3-yl)-2H-chromen-2-one (5l)
Yield 70%; m.p. 293–296 C; Mol. Formula: C30H20BrFN2O5;
IR (KBr, cm1): 3012 (ArAH), 1712 (coumarin C‚O), 1682rin derivatives containing pyrazole and indenone rings as potent anti-
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(DMSO d6, 400 MHz) d: 3.23 (3H, s, OCH3), 3.40 (3H,
s,OCH3), 4.72 (2H, s, CH2), 7.38–8.87 (10H, m, ArAH), 8.89
(1H, s, CH methine), 9.79 (1H, s, C‚CAH), 13CNMR
(CDCl3) d: 44.0 (CH2), 57.4 (2-OCH3), 104.4, 107.2, 109.1,
112.0 (2C), 114.2, 116.4, 119.0, 121.7, 122.5, 125.3, 127.0,
131.5, 133.4 (2C), 136.2, 138.4, 142.4, 144.2, 148.3, 152.5,
155.4, 152.3,163.4, 166.4, 170.0 (coumarin C‚O), 175.0 (inde-
none C‚O). MS: m/z 586 [M+], 588 [M+2].
2.2. Pharmacology
2.2.1. Antioxidant activity
2.2.1.1. Free radical scavenging activity by DPPH method. Free
radical scavenging capacities of synthesized compounds were
determined according to the reported procedure (Braca
et al., 2001). The newly synthesized compounds at different
concentrations (25–100 lg/mL) were added to each test tube
and volume was made up to 4 mL using methanol. To this,
3 mL of 0.004% DPPH in methanol was added and the mix-
tures were incubated at room temperature under dark condi-
tion for 30 min. The absorbance was recorded at 517 nm
using a UV–Visible spectrophotometer (Shimadzu UV-1800,
Japan). Butylated hydroxyl toluene (BHT), dissolved in dis-
tilled water was used as a reference. Control sample was pre-
pared using the same volume without any compound and
BHT, 95% methanol served as blank. Test was performed in
triplicate and the results were averaged. Radical scavenging
activity was calculated using the formula:
% of radical scavenging activity¼½ðAcontrolAtestÞ=Acontrol100
where Acontrol is the absorbance of the control sample (DPPH
solution without test sample) and Atest is the absorbance of the
test sample (DPPH solution + test compound).
2.2.2. Chelating effect on ferrous ions
The chelating effect was determined according to the literature
method (Nevcihan et al., 2010). The test solution (2 mL) of dif-
ferent concentrations (25–100 lg/mL) in methanol was added
to a solution of 2 mM FeCl2 (0.05 mL) and the reaction was
initiated by adding 5 mM ferrozine (0.2 mL) and the total vol-
ume was adjusted to 5 mL with methanol. Then, the mixture
was shaken vigorously and left at room temperature for
10 min. Absorbance of the solution was measured spectropho-
tometrically at 562 nm. EDTA was used as a standard. The
inhibition percentage of ferrozine-Fe+2 complex formations
was calculated using the formula:
Metal chelating effect ð%Þ ¼ ½ðAcontrol  AsampleÞ=Acontrol  100
where Acontrol is the absorbance of control (control contains
FeCl2 ferrozine complex) and Asample is the absorbance of test
compounds. Test was performed in triplicate, and the results
were averaged.
2.2.3. Total reductive capability
The reductive capability of the compounds was determined
according to the literature method (Oyaizu, 1986). The solu-
tion of test compound (1 mL) at different concentrations
(25–100 lg/mL) in methanol was mixed with phosphate buffer
(2.5 mL, 0.2 mol/L pH 6.5) and potassium ferricyanidePlease cite this article in press as: Kenchappa, R. et al., Synthesis of couma
oxidant and antihyperglycemic agents. Arabian Journal of Chemistry (201(2.5 mL, 1%) and the mixture was incubated at 50 C for
20 min. At the end of the incubation, trichloroacetic acid
(2.5 mL, 10%) was added to the mixture, and centrifuged at
3000 rpm for 10 min. The upper layer solution was collected
and mixed with distilled water (2.5 mL) and 0.1% ferric chlo-
ride (0.5 mL, 0.1%) solution. The absorbance was measured at
700 nm against a blank. Test was performed in triplicate, and
the results were averaged.
2.2.4. In-vivo anti-hyperglycemic activity
2.2.4.1. Animal housing and maintenance. Adult Wistar rats
weighing between 200 and 300 g were used in this study. Ani-
mals were taken care as per the Regulations of Committee for
the Purpose of Control and Supervision of Experiments on
Animals (CPCSEA), Government of India. The ‘Form B’ for
carrying out animal experimentation was reviewed and
approved by the Institutional Animal Ethics Committee
(IAEC). Animals were maintained in a controlled environment
with 22–25 C temperature, 50–60% humidity, a light/dark
cycle of 12 h each and 15–20 air changes per hour. Animals
were fed, ad libitum, with certiﬁed Irradiated Laboratory
Rodent Diet (Nutri lab brand, Tetragon Chemie Pvt. Ltd,
Bangalore) except during the fasting & study period.
2.2.4.2. Oral glucose tolerance test in normal rats. Overnight
fasted normal rats were divided into twenty groups of six rats
each. They were orally administered with vehicle, six synthe-
sized compounds 5a, 5c and 5e–5h (10, 50 and 100 mg/kg)
and metformin (60 mg/kg), respectively. Glucose (2 g/kg) was
fed 30 min after the administration of compounds (Shirwaikar
and Rajendran, 2006). Blood was withdrawn through the tail
vein at 0, 30, 60 and 120 min of glucose administration to
observe changes in the blood glucose level.
2.2.4.3. Hypoglycemic activity assay. Test substance and refer-
ence standard (metformin) suspension were prepared with vehi-
cle containing 0.5% (w/v) of carboxymethyl cellulose and 0.1%
Tween 80. Streptozotocin (STZ) was dissolved in citrate buffer
(pH 4.5) and nicotinamide in normal saline solution (0.9%
NaCl solution). Diabetes was induced in overnight fasted rats
by a single intraperitoneal (i.p.) injection of 60 mg/kg of strep-
tozotocin and 120 mg/kg of nicotinamide in Wistar rats (of
both sexes) (Shirwaikar and Rajendran2006). Hyperglycemia
was conﬁrmed by the elevated non fasting glucose levels in
blood, determined 48 h after diabetes induction using a Glu-
cometer (Accu-check Advantage, Roche diagnostics Mann-
heim, Germany) and strips. Animals with blood glucose
concentrations more than 250 mg/dL were used for the study.
Each study group involved 6 diabetic rats. Cage cards indicat-
ing the study number, animal number & treatment group
details were afﬁxed to the corresponding cages. Standard drug
and test compounds were given orally at 10, 50 and 100 mg/kg.
The change in the body weight of rats after induction diabetes
was noted. The blood sample was collected from caudal vein of
the tested rats. Reduction in blood glucose produced by the
compound was recorded on 1st, 2nd, 3rd, 4th, 7th and 14th
day. At the end of experiment, animals were euthanized by
CO2 asphyxiation and organ weights were recorded.
Statistical analysis was performed by One-way ANOVA
followed by Dunnett’s multiple comparison tests. P< 0.05
was considered as a signiﬁcant change.rin derivatives containing pyrazole and indenone rings as potent anti-
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6 R. Kenchappa et al.3. Result and discussion
3.1. Chemistry
Reaction sequences employed for the synthesis of title com-
pounds is shown in Scheme 1. The key intermediates, 6-substi-
tuted-3-{(1E)-1-[2-(4-substituted) hydrazinylidene] ethyl}-2H-
chromen-2-one (3a–l) were synthesized by stirring the reaction
mixture of 6-substituted 3-acetyl coumarin (1a–b) with p-substi-
tuted phenyl hydrazine hydrochloride (2a–f) in dry ethanol
using sodium acetate at room temperature (Goudarshivannanavar
et al., 2009). Vilsmeier formylation of these compounds (3a–l)
at reﬂux temperature for 6 h gave the expected formyl pyrazole
derivatives (4a–l) in good yield. Further, Claisen–Schmidt
condensation of 3-(6-substituted-2-oxo-2H-chromen-3-yl)-1-
(4-substituted)-1H-pyrazole-4-carbaldehyde derivatives (4a–l)
with 5,6-dimethoxy-2,3-dihydro-1H-inden-1-one at room
temperature for 8 h led to the formation of corresponding
6-substituted-3-(1-(4-substituted)-4-((Z)-(5,6-dimethoxy-1-oxo-
1H-inden-2(3H)-ylidene)methyl)-1H-pyrazol-3-yl)-2H-chromen-
2-onederivatives (5a–l).
All pyrazole coumarin indenone analogs provided satisfac-
tory spectral data. In IR spectra, bands in the region 1671–
1691 cm1 were attributed to the –CHO group of (4a–l) series
and bands in the region 1625, 1520 cm1 were attributed to
symmetric and asymmetric frequency of the NO2 group of
the compound 4j. Bands at 1703–1713 cm1 obtained fromComp. R R1
a H H
b Br H
c H 4-Cl
d Br 4-Cl
e H 4-CH3
f Br 4-CH3
O
O
O
R
+
NH-NH3
+
Cl
-
R
1
CH3COO
CH
(1a-b) (2a-f)
(5a-l)
O N N
O
O
O
O
R
R
1
O
O
Scheme 1 Synthesis of 6-substituted-3-(1-(4-substituted)-4-((Z)-(5,6
yl)-2H-chromen-2-one (5a–l) derivatives.
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frequencies correspond to the C‚O groups of indenone. In
1HNMR spectra, the singlet between d 9.94–10.23ppm corre-
sponds to the presence of the –CHO group of the compounds
4(a–l). The absence of aldehyde proton signal at d 9.94–
10.21 ppm and the presence of a signal in the range d 9.68–
9.91 ppm (C‚CAH) support the formation of compounds
5(a–l) and the singlet in the range of 8.50–9.2 ppm due to the
methine proton. In 13C-NMR, signal at d 171.5–176.3 assigned
to carbonyl carbon in indenone, signal at d 168.2–169.2 con-
ﬁrmed lactone carbonyl of 5(a–l) and the signal between 43-
49 ppm due to CH2 carbon in the indenone ring. Signal that
appeared between 56.2-58.6 corresponds to the OCH3 carbon
in indenone ring. Other signals are in good agreement with
the target compounds.
3.2. Pharmacology
3.2.1. Free radical scavenging activity by DPPH method
The newly synthesized compounds (5a–l) were screened for
their radical scavenging activity by the DPPH method. The
activity results of the newly synthesized compounds are repre-
sented in Fig. 1.
We found that, most of the compounds showed consider-
able free radical scavenging activity. Compounds 5e–h have
shown the strongest free radical scavenging activity among
the tested compounds with IC50 ranging between 54.14 andComp. R R1
g H 4-OCH3
h Br 4-OCH3
i H 4-NO2
j Br 4-NO2
k H 4-F
l Br 4-F
O
O
N NH
R
1
R
Na/EtOH
O
N
N
OHC
O
R
1R
DMF/POCl3
3OH/NaOH
(3a-l)
(4a-l)
O
-dimethoxy-1-oxo-1H-inden-2(3H)-ylidene) methyl)-1H-pyrazol-3-
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Synthesis of coumarin derivatives containing pyrazole and indenone rings 759.76 lg/mL. The compound with no substitution on phenyl
ring 5a with IC50 64.75 lg/mL and the compounds 5c and 5k
substituted with halogens showed good scavenging effect with
IC50 70.14 and 88.29 lg/mL. The other tested compounds dis-
played moderate to good scavenging activity. The IC50 value
of the reference standard BHT was recorded as 46.95 lg/mL.
3.2.2. Chelating effects on ferrous ions
The iron chelating studies measure the ability of antioxidants
to compete with ferrozine in chelating ferrous ion (Elmastas
et al., 2006). It was reported that the compounds containing
two or more functional groups like OH, SH, COOH, C‚O,
NR2 and oxygen in a favorable structure–function conﬁgura-
tion can show the activity of metal chelation (Yuan et al.,
2005). The ferrous ion-chelating activity of the newly synthe-
sized compounds is represented in Fig. 2. From the activity
data it was observed that, the compounds substituted with
electron donating groups on the indenone ring and phenyl ring
5e–5h exhibited excellent activity with IC50 value 53.75–
62.30 lg/mL. Compounds 5a and 5k displayed satisfactory
activity with IC50 65.95 and 7.76 lg/mL. Compound 5cStd - BHT
Figure 1 DPPH free radical scavenging
Std-EDTA
Figure 2 Ferrous ion chelating assa
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value of the reference standard EDTA was recorded as
44.11 lg/mL.
3.2.3. Total reductive capability
Fe(III) reduction is often used as an indicator of electron
donating activity, which is an important mechanism of pheno-
lic antioxidant action. In the reducing power assay, the pres-
ence of antioxidant in the synthesized compounds would
result in the reduction of Fe+3 to Fe+2 complex by donating
an electron. The amount of Fe+2 complexes was then moni-
tored by measuring the formation of Perl’s Prussian blue at
700 nm. Increasing absorbance at 700 nm indicates an increase
in reducing ability (Nabavi et al., 2008). The results are repre-
sented in Fig. 3. It was found that the reducing power of all the
synthesized compounds increased with the increase in their
concentrations. The best reducing power was presented by
the compound 5g containing two methoxy groups on indenone
and a methoxy group on phenyl ring with IC50 58.01 lg/mL.
Compounds substituted with electron donating groups 5e, 5f
and 5h exhibited good activity with IC50 ranging between 50assay (%) of test compounds (5a–l).
y (%) of test compounds (5a–l).
rin derivatives containing pyrazole and indenone rings as potent anti-
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8 R. Kenchappa et al.62.57 and 69.17 lg/mL. The other tested compounds showed
less activity compared to standard. The IC50 value of the refer-
ence standard Butylated hydroxyl anisole BHA was recorded
as 50.00 lg/mL.
IC50 values of DPPH radical scavenging ferrous ion chelat-
ing activity and total reductive capability of test compounds
are given in Table 1.
3.2.4. Oral glucose tolerance test in normal rats
Oral glucose tolerance tests of synthesized compounds demon-
strated the highest blood glucose level at 30 min following glu-
cose administration, with decreasing blood glucose levels
thereafter (Figs. 4–6). Compared with the groups, i.e. normal
control, standard and with the tested compounds, compounds
5g and 5e showed a signiﬁcant reduction in the blood glucose
level. Additionally at 120 min following glucose administra-
tion, the 100 mg/kg 5g and 5e groups had signiﬁcantly
(P 6 0.005) a greater drop in blood glucose than the 10 andStd-BHA
Figure 3 Total reductive capability a
Table 1 Half maximum inhibition concentration (IC50) values for
reductive capability activity of test compounds.
Compounds DPPH (IC50 lg/mL) Fe
+2 ion Chelating a
5a 64.75 ± 0.11 65.95 ± 0.11
5b 107.7 ± 0.32 105.01 ± 0.31
5c 70.14 ± 0.10 93.94 ± 0.29
5d 185.24 ± 0.15 189.29 ± 0.21
5e 56.19 ± 0.18 53.75 ± 0.15
5f 59.76 ± 0.21 59.45 ± 0.20
5g 54.14 ± 0.13 56.89 ± 0.20
5h 57.73 ± 0.13 62.30 ± 0.17
5i 92.15 ± 0.17 117.36 ± 0.13
5j 101.41 ± 0.13 153.87 ± 0.13
5k 88.29 ± 0.21 70.76 ± 0.13
5l 141.56 ± 0.13 131.02 ± 0.13
Stda,b,c 46.95 ± 0.17 44.11 ± 0.15
Each value is expressed as mean ± SD of three replicates.
a Std-BHT is used as standard for DPPH radical scavenging activity.
b Std-EDTA is used as a standard for Fe+2 ion chelating activity.
c Std-BHA is used as a standard for reductive capability.
Please cite this article in press as: Kenchappa, R. et al., Synthesis of couma
oxidant and antihyperglycemic agents. Arabian Journal of Chemistry (20150 mg/kg groups. The other tested groups exhibited moderate
to good decrease in the blood glucose level.
3.2.5. In-vivo anti-hyperglycemic activity
The antidiabetic potential of the newly synthesized compounds
was evaluated in STZ and nicotinamide induced T2DM in
Wistar rats (Watcho et al. 2012). Blood glucose levels of com-
pounds 5a, 5c and 5e–5h in diabetes in STZ/nicotinamide
model were checked for 14 days.
Compounds 5g and 5e having an electron donating group
on the phenyl ring showed prominent decrease in glucose con-
centration (115 and 138 mg/dL) with the dose of 100 mg/kg. It
was interesting to note that the compound 5h substituted with
electron withdrawing (Br) as well as electron donating (OCH3)
groups showed moderate to good activity. No signiﬁcant
decrease in the plasma glucose level was observed in com-
pound 5f. Compounds 5a and 5c showed less activity by
increase in the plasma glucose level (278 mg/dL and 387 mg/dL)ssay (%) of test compounds (5a–l).
DPPH free radical scavenging, ferrous ion chelating and total
ctivity (IC50 lg/mL) Total reductive capability (IC50 lg/mL)
73.09 ± 0.11
108.17 ± 0.31
84.21 ± 0.29
217.20 ± 0.21
62.57 ± 0.15
69.17 ± 0.20
58.01 ± 0.20
65.52 ± 0.17
157.96 ± 0.13
289.02 ± 0.13
92.59 ± 0.13
133.90 ± 0.13
50.00 ± 0.15
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Figure 4 Effect of synthesized compounds on oral glucose tolerance at the concentration of 10 mg/kg of body weight.
Figure 5 Effect of synthesized compounds on oral glucose tolerance at the concentration of 50 mg/kg of body weight.
Figure 6 Effect of synthesized compounds on oral glucose tolerance at the concentration of 100 mg/kg of body weight.
Synthesis of coumarin derivatives containing pyrazole and indenone rings 9with the dose of 100 mg/kg. The lowering of plasma glucose in
diabetic rats after treatment with compounds 5a, 5c and 5e–h
at concentrations 10, 50 and 100 mg/kg is represented in
Fig. 7–9, respectively.
Treatment with the test substance for 14 days showed an
increase in body weight (Table 2) compared to diabetic con-
trol; no signiﬁcant increase in liver weight at 100 mg/kg; and
no change in kidney weight were observed with treatment.Please cite this article in press as: Kenchappa, R. et al., Synthesis of couma
oxidant and antihyperglycemic agents. Arabian Journal of Chemistry (2014. Conclusion
A new series of coumarin derivatives containing pyrazole and
indenone moiety have been synthesized and the synthesized
compounds were well characterized by IR, 1HNMR, 13CNMR
and LC–MS spectroscopic methods. Our adopted method for
the synthesis of target compounds was effective in terms of
time and yield. The reaction conditions are simple, and theyrin derivatives containing pyrazole and indenone rings as potent anti-
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Figure 7 Signiﬁcant lowering of plasma glucose in diabetic rats treated with compounds at the concentration of 10 mg/kg of body
weight.
Figure 8 Signiﬁcant lowering of plasma glucose in diabetic rats treated with compounds at the concentration of 50 mg/kg of body
weight.
Figure 9 Signiﬁcant lowering of plasma glucose in diabetic rats treated with compounds at the concentration of 100 mg/kg of body
weight.
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Table 2 Effect of synthesized compounds on body weight in STZ–nicotinamide induced diabetic rats.
Sl no. Loss or gain of body weight of experimental rats
10 mg/kg bw 50 mg/kg bw 100 mg/kg bw
0th day 14th day 0th day 14th day 0th day 14th day
Normal control 195.01 ± 4.08 224.09 ± 9.94 ND ND ND ND
Diabetic control 190.56 ± 9.45 168.13 ± 15.83 ND ND ND ND
Standard 193.45 ± 5.03a 197.07 ± 3.57 a 198.37 ± 4.03a 203.67 ± 5.57a 199.00 6.03a,b 218.07 ± 3.57 a
5a 191.51 ± 4.12 192.08 ± 2.34 190.33 ± 2.14 193.25 ± 3.47 195.00 ± 3.13a 193.05 ± 2.43a
5c 188.51 ± 2.18 190.08 ± 2.04a 190.33 ± 2.11a,b 189.25 ± 4.17 194.00 ± 3.21 192.12 ± 2.43
5e 189.23 ± 4.23a,b,c 192.01 ± 3.57 194.31 ± 2.03a 200.25 ± 4.27 196.00 ± 2.03 210.17 ± 5.18
5f 188.41 ± 3.13 191.05 ± 2.34 192.23 ± 3.12a,b,c 196.25 ± 2.17 195.00 ± 3.13a 197.04 ± 2.43
5g 190.35 ± 3.03a 194.04 ± 2.67 a 196.37 ± 2.21 201.67 ± 3.24a 198.00 ± 3.43 216.02 ± 2.34a,b
5h 192.27 ± 3.13 193.08 ± 4.54 195.33 ± 4.02 199.25 ± 5.57 200.00 ± 2.03a 206.07 ± 4.57
Values are mean ± SEM of 6 animals in each group.
a P< 0.05 compared with the normal.
b P< 0.05 compared with diabetic control.
c P< 0.05 compared with the glibenclamide treated group. ND-Not determined.
Synthesis of coumarin derivatives containing pyrazole and indenone rings 11are not sensitive to oxygen and water, which make it easy to
operate at room temperature. The presence of pyrazole ring
endows these species with important pharmacological and
therapeutic interest. From the structure–activity relationship
studies it revealed that, the presence of electron withdrawing
group/halogen substituted compounds showed good antioxi-
dant property. In case of antihyperglycemic activity, com-
pounds 5g and 5e showed prominent antidiabetic activity.
Further research needs to be done to fully understand how
the synthesized compounds are working in the pancreas and
by what mechanism it is able to lower glucose levels in Strep-
tozotocin–nicotinamide induced diabetic mice.
Acknowledgements
The authors are thankful to the Chairman, Department of
Industrial Chemistry, Kuvempu University, Shankaraghatta
for providing the laboratory facilities. One of the authors
(Kenchappa R.) is thankful to the UGC for the award of Rajiv
Gandhi National Fellowship (RGNF).
References
Ahmad, M., Siddiqui, H.L., Zia-ur-Rehman, M., Parvez, M., 2010.
Eur. J. Med. Chem. 45, 698–704.
Anju, D., Arun, N., Sayeed, A., 2012. Arabian J. Chem., doi.org/
10.1016/j.arabjc.2012.05.001.
Arteel, Antonello, A., Tarozzi, A., Morroni, F., Cavalli, A., Rosini,
M., Hrelia, P., Bolognesi, M.L., Melchiorre, C., 2006. J. Med.
Chem. 49, 6642–6645.
Braca, A., Tommasi, N.D., Bari, L.D., Pizza, C., Politi, M., Morelli, I.,
2001. J. Nat. Prod. 64, 892–895.
Braulio, L.O., Henry, I.I., Jairo, Q.P., 1999. J. Heterocycl. Chem. 36,
635–638.
Chimenti, F., Bizzarri, B., Bolasco, A., Secci, D., Chimenti, P.,
Granese, A., Carradori, S., Rivanera, D., Zicari, A., Scaltrito,
M.M., Sisto, F., 2010. Bioorg. Med. Chem. Lett. 20, 4922–4926.
Chun, O.K., Kim, D.O., Lee, C.Y., 2003. J. Agric. Food Chem. 51,
8067–8072.
Chunhuan, H., Xiaowen, J., Yingming, P., Hengshan, W., Kai, W.,
Min, L., Lizhu, Y., 2010. Med. Chem. Res. 19, 448–461.
Elmastas, M., Gu¨lc¸in, I., Isildak, O¨., Ku¨freviog˘lu, O¨.I., Ibaog˘lu, K.,
Aboul-Enein, H.Y., 2006. J. Iran Chem. Soc. 3, 258–266.Please cite this article in press as: Kenchappa, R. et al., Synthesis of couma
oxidant and antihyperglycemic agents. Arabian Journal of Chemistry (201Es-Saﬁ, N., Ghidouche, S., Ducrot, P.H., 2007. Molecules 12, 2228–
2258.
Gajanan, W., Rahul, A., Neha, K., Ravi, R., Naveen, K.K., Dinkar,
S., 2010. Bioorg. Med. Chem. Lett. 20, 4675–4678.
Gegory, R.B., Greg, A., Beverly, B., Christine, B., Bork, B., Bryan,
F.B., Michele, E., Jiaping, G., Prasad, K., Robert, J.S., Herbert,
F.S., Mary, W., David, D.X., 2001. J. Med. Chem. 44 (16), 2601–
2611.
Ghate, M., Kusanur, A.R., Kulkarni, V.M., 2005. Eur. J. Med. Chem.
40, 882.
Gireesh, T., Ravindra, R.K., Pramod, P.K., Sheetal, B.M., 2011.
Arabian J. Chem., doi:10.1016/j.arabjc.2011.04.006.
Goudarshivannanavar, B.C., Jayadevappa, H., Mahadevan, K.M.,
2009. Indian J. Chem. 48B, 1419–1423.
Guo, J.N., Weng, X.C., Wu, H., Li, Q.H., Bi, K.S., 2005. Food Chem.
91, 287–292.
Hyun, D.H., Hernandez, J.O., Mattson, M.P., de Cabo, R., 2006.
Aging Res. Rev. 5, 209–220.
Isloor, A.M., Kalluraya, B., Rao, M., 2000. J. Saudi Chem. Soc. 4 (3),
265–270.
Jovanovic, S.V., Steenken, S., Tosic, M., Marjanovic, B., Simic, M.G.,
1994. J. Am. Chem. Soc. 116, 4846–4851.
Karali, N., Kocabalkanli, A., Gursoy, A., Ates, O., 2002. Farmaco 57,
589–593.
Kenchappa, R., Bodke, Y.D., Chandrashekar, A., Telkar, Sandeep,
Manjunatha, K.S., Aruna Sindhe, M., 2013a. Arabian J. Chem.,
doi.org/10.1016/j.arabjc.2013.03.020.
Kenchappa, R., Bodke, Y.D., Peethambar, S.K., SandeepTelkar,
Venkatesh, K.B., 2013b. Med. Chem. Res. 22, 4787–4797.
Khan, A.I., Kulkarni, V.M., Gopal, M., Shahabuddin, S.M., Chung-
Ming, S., 2005. Bioorg. Med. Chem. Lett. 15, 3587.
King, H., Rewers, M., 1993. Diabetes Care 16, 157–177.
Kus, V., Flachs, P., Kuda, O., Bardova, K., 2011. PLoS One 6 (11),
e27126. http://dx.doi.org/10.1371/journal.pone.0027126.
Lim, Y.Y., Murtijaya, J., 2007. Food Sci. Technol. 40, 1664–1669.
Mamta, R., Mohamad, Y., Salman, A.K., Sahota, P.P., Pandove, G.,
2010. Arabian J. Chem., doi:10.1016/j.arabjc.2010.10.036.
Nabavi, S.M., Ebrahimzadeh, M.A., Nabavi, S.F., Hamidinia, A.,
Bekhradnia, A.R., 2008. Pharmacol. Online 2, 560–567.
Neogi, P., Lakner, F.J., Medicherla, S., Cheng, J., Dey, D., Gowri, M.,
Nag, B., Sharma, S.D., Pickford, L.B., Gross, C., 2003. Bioorg.
Med. Chem. 11, 4059–4067.
Nevcihan, G., Cengiz, S., Bektas, T., Halil, S.M., 2010. Food Sci.
Biotech. 19 (3), 691–696.
Oyaizu, M., 1986. Jpn. J. Nutr. 44, 307–315.rin derivatives containing pyrazole and indenone rings as potent anti-
4), http://dx.doi.org/10.1016/j.arabjc.2014.05.029
12 R. Kenchappa et al.Padmaja, A., Rajasekhar, C., Muralikrishna, A., Padmavathi, V.,
2011. Eur. J. Med. Chem. 46, 5034–5038.
Rizk, H.F., El-Badawi, M.A., Ibrahim, S.A., El-Borai, M.A., 2011.
Arabian J. Chem. 4, 37–44.
Saija, A., Scalese, M., Lanza, M., Marzullo, D., Bonina, F., Castelli,
F., 1995. Free Radical Biol. Med. 19, 481–486.
Saltiel, A.R., Kahn, C.R., 2001. Nature 414, 799–806.
Sangle, G.V., Lauffer, L.M., Grieco, A., 2012. Endocrinology 153, 564.
Sas, K., Robotka, H., Toldi, J., Vecsei, L., 2007. J. Neurol. Sci. 257,
221–239.
Shirwaikar, A., Rajendran, K., 2006. J. Ethnopharmacol. 107 (2), 285–
290.
Singh, U., Jialal, I., 2006. Pathophysiology 13, 129–142.Please cite this article in press as: Kenchappa, R. et al., Synthesis of couma
oxidant and antihyperglycemic agents. Arabian Journal of Chemistry (201Smith, M.A., Rottkamp, C.A., Nunomura, A., Raina, A.K., Perry, G.,
2000. Biochim. Biophys. Acta 1502, 139–144.
Stancho, S., Georgi, M., Frank, J., Ilia, M., 2008. Eur. J. Med. Chem.
43, 694–706.
Vijaya Laxmi, S., Suresh, K.B., Rajitha, B., 2013. Med. Chem. Res. 22,
768–774.
Watcho, P., Achountsa, J.H.G., Mbiakop, C.U., Wankeu, N.M.,
Nguelefack, T.B., Kamanyi, A., 2012. BMC Complem. Altern.
Med. 12, 264.
Xin-Hua, L., Jun, L., Jing, B.S., Bao-An, S., Xing-Bao, Qi., 2012. Eur.
J. Med. Chem. 51, 294–299.
Yuan, Y.V., Bone, D.E., Carrington, M.F., 2005. Food Chem. 91,
485–494.rin derivatives containing pyrazole and indenone rings as potent anti-
4), http://dx.doi.org/10.1016/j.arabjc.2014.05.029
